Results 41 to 50 of about 5,353 (192)

Macaque bone marrow pDC express lower CD123 and HLA-DR, display higher percentages of CD34+ and Ki67+ precursors than blood pDC, and are poor IFN-I producers.

, 2014
(A) CD34+ and Ki67+ pDC-precursor frequencies are higher in the bone marrow (BM) than in the blood (non-infected macaques, n = 6), and both CD123 and HLA-DR expressions are lower in BM pDC than blood pDC.
Christine Rogez-Kreuz (517538), Bruno Vaslin (517540), Antonio Cosma (2321), Rémi Cheynier (170852), Nathalie Dereuddre-Bosquet (114584), Aurélien Corneau (517539), Timothée Bruel (337070), Thomas Démoulins (517537), Stéphanie Dupuy (188131), Roger Le Grand (51396), Jacques Dutrieux (323478)   +10 more
core   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Characterization of HLA-DR⁺ non-DC population.

, 2021
(A) Gating strategy for neutrophils in the blood: Within the lineage (CD3, CD15, CD19, CD20, CD56, CD66b) positive cells neutrophils were gated as CD16+ and CD88/89+. (B) UMAP clustering of one representative COVID-19 patient.
Anne Hilgendorff (91403), Anne B. Krug (6919562), Jan Kranich (49284), Thomas Brocker (199030), Konstantin Stark (3809302), Maximilian Muenchhoff (621654), Benjamin Schubert (3585338), Michael von Bergwelt-Baildon (223983), Alexandra Leutbecher (11492484), Simon Rothenfusser (3934535), Johannes C. Hellmuth (11530192), Lisa Rausch (11530180), Paul R. Wratil (11530183), Linus Rinke (11296773), Oliver T. Keppler (9107341), Marion Subklewe (139383), Konstantin Lutz (11530174), Dirk Baumjohann (11530189), Anna Reischer (11492487), Tobias Straub (55423), Elena Winheim (11296776), Johanna E. Huber (11530186), Clemens Scherer (10740653), Lina Wolfram (11530177)   +23 more
core   +1 more source

CASE REPORT: CML PROGRESSION TO AML-MR WITH CLONAL CHROMOSOMAL ABNORMALITIES

Hematology, Transfusion and Cell Therapy, 2023
Introduction: The advancement of chronic myeloid leukemia (CML) treatment through tyrosine kinase inhibitors (TKIs) has brought about a revolutionary transformation in patient outcomes, clinical responses, and survival rates.
S Lanes, WS Goulart, M Souza, L Mattos, MA Morais, AM Oba, C Pugliesi, R Prot-Siqueira, A Marinato   +8 more
doaj   +1 more source

A 3D Bioprinted Platform That Maintains the Functional Integrity of Primary AML Cells

Cell Proliferation, EarlyView.
This study presents a 3D bioprinted platform using gelatin‐hyaluronic acid hydrogels to enhance primary AML cell survival and proliferation while preserving stem‐like properties in vitro. By recapitulating in vivo‐like metabolic activity and drug resistance, this system offers a robust tool for preclinical drug screening and personalised therapy ...
Wanling Huang, Bo Deng, Nini Guo, Yiyi Ding, Zhangjingwen Xu, Yiwen Lu, Yue Ma, Qian Ren, Nan Wang, Pengyu Huang, Xiaotong Ma   +10 more
wiley   +1 more source

RUNX1 Mutations Cause a Myeloid Differentiation Block Leading to the Formation of a Long Term Expanding CD34+/CD33+/CD45RA+/CD123+ Cell Population

Blood, 2016
Abstract RUNX1 (AML1) is a transcription factor critically involved in normal haematopoiesis. Inactivating RUNX1 mutations have been frequently described in a variety of myeloid neoplasms, including high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Here, we aimed to functionally and molecularly define the actions
Gerritsen, Mylene, Tijchon, Esther, Mandoli, Amit, Martens, Joost H. A., Schuringa, Jan Jacob, Vellenga, Edo   +5 more
openaire   +2 more sources

Cutaneous involvement by myeloid leukaemias: challenging cases with important implications

Histopathology, EarlyView.
Myeloid leukaemias and precursors involving the skin are often challenging to diagnose with varied and overlapping clinical and histopathologic features. Nonetheless, they are critical for pathologists to recognize and accurately classify. This review discusses the clinical, histopathological and genetic features of myelodysplasia cutis (A) and ...
Alexandra C. Hristov
wiley   +1 more source

Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies

Frontiers in Immunology, 2022
The great clinical success of chimeric antigen receptor (CAR) T cells has unlocked new levels of immunotherapy for hematological malignancies. Genetically modifying natural killer (NK) cells as alternative CAR immune effector cells is also highly ...
Maren Soldierer, Arthur Bister, Arthur Bister, Corinna Haist, Corinna Haist, Aniththa Thivakaran, Sevgi Can Cengiz, Stephanie Sendker, Nina Bartels, Antonia Thomitzek, Denise Smorra, Maryam Hejazi, Markus Uhrberg, Kathrin Scheckenbach, Cornelia Monzel, Constanze Wiek, Dirk Reinhardt, Naghmeh Niktoreh, Helmut Hanenberg, Helmut Hanenberg   +19 more
doaj   +1 more source

ICSH Guidance on Bone Marrow Examination and Reporting

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease
Wendy N. Erber, Alexandar Tzankov, Olga Pozdnyakova, Hiromichi Matsushita, Gina Zini, Leonie Saft, on behalf of the International Council for Standardization in Haematology   +6 more
wiley   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: Report of two pediatric cases

Indian Journal of Pathology and Microbiology, 2015
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare subtype of acute leukemia that typically follows a highly aggressive clinical course in adults, whereas experience in children with this disease is very limited.
Preeti Ashok Dharmani, Neha Manish Mittal, P G Subramanian, Komal Galani, Yajamanam Badrinath, Pratibha Amare, Sumeet Gujral   +6 more
doaj   +1 more source